These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 23998705

  • 1. Does the pretreatment tumor sampling location correspond with metabolic activity on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy?
    Koolen BB, Elshof LE, Loo CE, Wesseling J, Vrancken Peeters MJ, Vogel WV, Rutgers EJ, Valdés Olmos RA.
    Eur J Radiol; 2013 Dec; 82(12):2353-8. PubMed ID: 23998705
    [Abstract] [Full Text] [Related]

  • 2. FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer.
    Koolen BB, Pengel KE, Wesseling J, Vogel WV, Vrancken Peeters MJ, Vincent AD, Gilhuijs KG, Rodenhuis S, Rutgers EJ, Valdés Olmos RA.
    Breast; 2013 Oct; 22(5):691-7. PubMed ID: 23414930
    [Abstract] [Full Text] [Related]

  • 3. 18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO.
    Gebhart G, Gámez C, Holmes E, Robles J, Garcia C, Cortés M, de Azambuja E, Fauria K, Van Dooren V, Aktan G, Coccia-Portugal MA, Kim SB, Vuylsteke P, Cure H, Eidtmann H, Baselga J, Piccart M, Flamen P, Di Cosimo S.
    J Nucl Med; 2013 Nov; 54(11):1862-8. PubMed ID: 24092940
    [Abstract] [Full Text] [Related]

  • 4. Comparison of whole-body PET/CT and PET/MRI in breast cancer patients: lesion detection and quantitation of 18F-deoxyglucose uptake in lesions and in normal organ tissues.
    Pace L, Nicolai E, Luongo A, Aiello M, Catalano OA, Soricelli A, Salvatore M.
    Eur J Radiol; 2014 Feb; 83(2):289-96. PubMed ID: 24331845
    [Abstract] [Full Text] [Related]

  • 5. Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in hybrid 18F-FDG PET/MRI in non-small cell lung cancer (NSCLC) lesions: initial results.
    Heusch P, Buchbender C, Köhler J, Nensa F, Beiderwellen K, Kühl H, Lanzman RS, Wittsack HJ, Gomez B, Gauler T, Schuler M, Forsting M, Bockisch A, Antoch G, Heusner TA.
    Rofo; 2013 Nov; 185(11):1056-62. PubMed ID: 23860802
    [Abstract] [Full Text] [Related]

  • 6. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, Schnall M, Alavi A.
    Cancer; 2008 Mar 01; 112(5):995-1000. PubMed ID: 18098228
    [Abstract] [Full Text] [Related]

  • 7. Combination of 18F-FDG PET/CT and diffusion-weighted MR imaging as a predictor of histologic response to neoadjuvant chemotherapy: preliminary results in osteosarcoma.
    Byun BH, Kong CB, Lim I, Choi CW, Song WS, Cho WH, Jeon DG, Koh JS, Lee SY, Lim SM.
    J Nucl Med; 2013 Jul 01; 54(7):1053-9. PubMed ID: 23670899
    [Abstract] [Full Text] [Related]

  • 8. Prognostic value of the quantitative metabolic volumetric measurement on 18F-FDG PET/CT in Stage IV nonsurgical small-cell lung cancer.
    Liao S, Penney BC, Zhang H, Suzuki K, Pu Y.
    Acad Radiol; 2012 Jan 01; 19(1):69-77. PubMed ID: 22142679
    [Abstract] [Full Text] [Related]

  • 9. Breast cancer with low FDG uptake: characterization by means of dual-time point FDG-PET/CT.
    Zytoon AA, Murakami K, El-Kholy MR, El-Shorbagy E, Ebied O.
    Eur J Radiol; 2009 Jun 01; 70(3):530-8. PubMed ID: 18395387
    [Abstract] [Full Text] [Related]

  • 10. Early Metabolic Response to Neoadjuvant Treatment: FDG PET/CT Criteria according to Breast Cancer Subtype.
    Groheux D, Majdoub M, Sanna A, de Cremoux P, Hindié E, Giacchetti S, Martineau A, de Roquancourt A, Merlet P, Visvikis D, Resche-Rigon M, Hatt M, Espié M.
    Radiology; 2015 Nov 01; 277(2):358-71. PubMed ID: 25915099
    [Abstract] [Full Text] [Related]

  • 11. Journal Club: Diagnostic value of (18)F-FDG PET/CT and MRI in predicting the clinicopathologic subtypes of invasive breast cancer.
    Miyake KK, Nakamoto Y, Kanao S, Tanaka S, Sugie T, Mikami Y, Toi M, Togashi K.
    AJR Am J Roentgenol; 2014 Aug 01; 203(2):272-9. PubMed ID: 25055259
    [Abstract] [Full Text] [Related]

  • 12. Diffusion weighted MRI and 18F-FDG PET/CT in non-small cell lung cancer (NSCLC): does the apparent diffusion coefficient (ADC) correlate with tracer uptake (SUV)?
    Regier M, Derlin T, Schwarz D, Laqmani A, Henes FO, Groth M, Buhk JH, Kooijman H, Adam G.
    Eur J Radiol; 2012 Oct 01; 81(10):2913-8. PubMed ID: 22197090
    [Abstract] [Full Text] [Related]

  • 13. [Value of fused 18F-FDG PET/CT images in predicting efficacy of neoadjuvant chemotherapy on breast cancer].
    Li D, Chen JH, Wang J, Ling R, Yao Q, Wang L.
    Ai Zheng; 2007 Aug 01; 26(8):900-4. PubMed ID: 17697556
    [Abstract] [Full Text] [Related]

  • 14. Pre-chemotherapy 18F-FDG PET/CT upstages nodal stage in stage II-III breast cancer patients treated with neoadjuvant chemotherapy.
    Koolen BB, Valdés Olmos RA, Vogel WV, Vrancken Peeters MJ, Rodenhuis S, Rutgers EJ, Elkhuizen PH.
    Breast Cancer Res Treat; 2013 Sep 01; 141(2):249-54. PubMed ID: 24002735
    [Abstract] [Full Text] [Related]

  • 15. Role of FDG-PET/CT in evaluating surgical outcomes of operable breast cancer--usefulness for malignant grade of triple-negative breast cancer.
    Ohara M, Shigematsu H, Tsutani Y, Emi A, Masumoto N, Ozaki S, Kadoya T, Okada M.
    Breast; 2013 Oct 01; 22(5):958-63. PubMed ID: 23756383
    [Abstract] [Full Text] [Related]

  • 16. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma.
    Park JW, Kim JH, Kim SK, Kang KW, Park KW, Choi JI, Lee WJ, Kim CM, Nam BH.
    J Nucl Med; 2008 Dec 01; 49(12):1912-21. PubMed ID: 18997056
    [Abstract] [Full Text] [Related]

  • 17. FDG-PET imaging for lymph node staging and pathologic tumor response after neoadjuvant treatment of non-small cell lung cancer.
    Ohtsuka T, Nomori H, Ebihara A, Watanabe K, Kaji M, Naruke T, Suemasu K, Uno K.
    Ann Thorac Cardiovasc Surg; 2006 Apr 01; 12(2):89-94. PubMed ID: 16702929
    [Abstract] [Full Text] [Related]

  • 18. Utility of MRI and PET/CT after neoadjuvant chemotherapy in breast cancer patients: correlation with pathological response grading system based on tumor cellularity.
    Kim T, Kang DK, An YS, Yim H, Jung YS, Kim KS, Kang SY, Kim TH.
    Acta Radiol; 2014 May 01; 55(4):399-408. PubMed ID: 23963151
    [Abstract] [Full Text] [Related]

  • 19. Dual-time-point 18F-FDG PET/CT versus dynamic breast MRI of suspicious breast lesions.
    Imbriaco M, Caprio MG, Limite G, Pace L, De Falco T, Capuano E, Salvatore M.
    AJR Am J Roentgenol; 2008 Nov 01; 191(5):1323-30. PubMed ID: 18941064
    [Abstract] [Full Text] [Related]

  • 20. 18F-FDG PET and CT/MRI in oral cavity squamous cell carcinoma: a prospective study of 124 patients with histologic correlation.
    Ng SH, Yen TC, Liao CT, Chang JT, Chan SC, Ko SF, Wang HM, Wong HF.
    J Nucl Med; 2005 Jul 01; 46(7):1136-43. PubMed ID: 16000282
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.